담도폐쇄증 치료제 시장 보고서(2026년)

Biliary atresia therapeutics refer to pharmaceutical products and medical treatment methods used to manage biliary atresia, a rare liver disease characterized by the blockage or absence of bile ducts. These therapeutic approaches are intended to enhance bile flow, minimize liver damage, manage associated complications, and preserve liver function.

The primary treatment types of biliary atresia therapeutics include surgical procedures, medication, liver transplantation, and other treatment types. Surgical procedures refer to medical interventions such as the Kasai portoenterostomy that help restore bile flow and enhance liver function in patients with biliary atresia. These therapies are used across age groups including neonates, infants, and pediatric patients. They are administered through oral, injectable, and other routes of administration and are utilized by end users including hospitals, specialty clinics, ambulatory surgical centers, and others.

Tariffs are influencing the biliary atresia therapeutics market by increasing the cost of imported surgical equipment, transplantation supplies, specialty medications, diagnostic technologies, and pediatric care devices required for disease management and treatment. This is increasing treatment costs and creating supply chain challenges for surgical procedures, medication therapies, and liver transplantation segments, particularly in import-dependent regions such as Asia-Pacific and Latin America. Hospitals, specialty clinics, and ambulatory surgical centers are experiencing increased procurement expenses that may affect treatment accessibility and operational efficiency. However, tariffs are also encouraging domestic production of medical devices, regional pharmaceutical manufacturing, and investment in local healthcare infrastructure, strengthening long-term supply chain resilience within the market.

The biliary atresia therapeutics market size has grown strongly in recent years. It will grow from $1.02 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing awareness of pediatric liver disorders, improvements in kasai portoenterostomy outcomes, expansion of pediatric hepatology services, growing availability of liver transplantation programs, advancements in supportive nutritional care.

The biliary atresia therapeutics market size is expected to see strongly grown in the next few years. It will grow to $1.53 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of novel bile flow enhancing therapies, increasing adoption of personalized treatment approaches, expansion of pediatric specialty care infrastructure, rising investment in rare disease therapeutics, growth in advanced surgical intervention capabilities. Major trends in the forecast period include advancements in minimally invasive biliary surgery techniques, increasing adoption of early diagnosis and intervention programs, growing use of combination medication therapies for liver function support, expansion of pediatric liver transplantation programs, rising focus on post operative care and long term disease management.

The expansion of neonatal screening programs is expected to propel the growth of the biliary atresia therapeutics market going forward. Neonatal screening programs refer to systematic public health initiatives that test newborns shortly after birth to detect congenital, genetic, and metabolic disorders at an early stage. The expansion of neonatal screening programs is driven by increasing government initiatives and healthcare policies focused on the early detection and timely treatment of congenital and genetic disorders in newborns. The expansion of neonatal screening programs enables the earlier identification of affected newborns, allowing timely medical intervention and increasing the demand for effective treatment approaches to manage disease progression and improve clinical outcomes. For instance, in March 2026, according to touchENDOCRINOLOGY, a UK-based peer-reviewed journal, the UK National Screening Committee (UK NSC) launched a consultation on newborn screening for biliary atresia, a rare liver disease affecting approximately 1 in 17,000 babies in the UK, where early detection is critical because treatment within the first two months significantly improves outcomes, although uncertainty remains regarding the effectiveness of population-wide screening. Therefore, the expansion of neonatal screening programs is driving the growth of the biliary atresia therapeutics market.

Leading companies operating in the biliary atresia therapeutics market are focusing on advancing clinical trials to develop innovative treatment options, such as ileal bile acid transporter (IBAT) inhibitor-based therapies, to improve bile flow, reduce liver damage, and delay or prevent the need for liver transplantation in pediatric patients. IBAT inhibitor-based therapies refer to oral small-molecule drugs that work by blocking bile acid reabsorption in the intestine, thereby reducing toxic bile acid buildup in the liver, improving liver function, and supporting better clinical outcomes in cholestatic liver diseases such as biliary atresia. For example, in May 2023, Mirum Pharmaceuticals, a US-based biopharmaceutical company, announced the completion of enrollment in its Phase 2b EMBARK study evaluating LIVMARLI (maralixibat) oral solution for pediatric patients with biliary atresia. The study is a global, double-blind, randomized, placebo-controlled trial designed to assess the efficacy and safety of the therapy in infants who had previously undergone the Kasai procedure (hepatoportoenterostomy). The EMBARK study represents the first completed randomized clinical trial of an ileal bile acid transporter (IBAT) inhibitor for biliary atresia, with topline results expected in the second half of 2023, and is expected to provide important insights into improving liver function and delaying disease progression in this rare pediatric liver disorder.

In March 2023, Ipsen S.A., a France-based biopharmaceutical company, acquired Albireo Pharma Inc. for $952 million. Through this acquisition, Ipsen S.A. aimed to significantly expand its rare disease franchise, particularly in rare pediatric and cholestatic liver diseases, by adding innovative bile acid modulation therapies and strengthening its late-stage and commercial pipeline in hepatology. Albireo Pharma Inc. is a US-based biotechnology company that specializes in developing Bylvay (odevixibat) as a potential therapeutic for biliary atresia.

Major companies operating in the biliary atresia therapeutics market are Ipsen S.A.; Mirum Pharmaceuticals Inc.; CANbridge Pharmaceuticals Inc.

North America was the largest region in the biliary atresia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary atresia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biliary atresia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biliary atresia therapeutics market consists of sales of corticosteroids, antibiotics, antiviral drugs, bile acid therapies, immunosuppressants, nutritional supplements, liver support medications, and related therapeutic products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, healthcare providers, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The biliary atresia therapeutics market research report is one of a series of new reports from The Business Research Company that provides biliary atresia therapeutics market statistics, including biliary atresia therapeutics industry global market size, regional shares, competitors with a biliary atresia therapeutics market share, detailed biliary atresia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the biliary atresia therapeutics industry. This biliary atresia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biliary Atresia Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biliary atresia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biliary atresia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biliary atresia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment Type: Surgical Procedures; Medication; Liver Transplantation; Other Treatment Types
• 2) By Age Group: Neonates; Infants; Pediatric Patients
• 3) By Route Of Administration: Oral; Injectable; Other Route Of Administrations
• 4) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Surgical Procedures: Kasai Portoenterostomy; Minimally Invasive Biliary Surgery; Robotic Assisted Biliary Surgery; Revision Surgical Procedures
• 2) By Medication: Corticosteroid Therapy; Antibiotic Therapy; Immunosuppressive Therapy; Bile Acid Therapy; Nutritional Supplement Therapy
• 3) By Liver Transplantation: Living Donor Liver Transplantation; Deceased Donor Liver Transplantation; Split Liver Transplantation; Pediatric Liver Retransplantation
• 4) By Other Treatment Types: Supportive Nutritional Care; Post Operative Care Management; Pediatric Hepatology Monitoring; Palliative Care Services
• Companies Mentioned: Ipsen S.A.; Mirum Pharmaceuticals Inc.; CANbridge Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Biliary Atresia Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Biliary Atresia Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Biliary Atresia Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Biliary Atresia Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Advancements In Minimally Invasive Biliary Surgery Techniques
  • 4.2.2 Increasing Adoption Of Early Diagnosis And Intervention Programs
  • 4.2.3 Growing Use Of Combination Medication Therapies For Liver Function Support
  • 4.2.4 Expansion Of Pediatric Liver Transplantation Programs
  • 4.2.5 Rising Focus On Post Operative Care And Long Term Disease Management

5. Biliary Atresia Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Ambulatory Surgical Centers
• 5.4 Pediatric Liver Transplant Centers
• 5.5 Other End Users

6. Biliary Atresia Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Biliary Atresia Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Biliary Atresia Therapeutics PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Biliary Atresia Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Biliary Atresia Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Biliary Atresia Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Biliary Atresia Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Biliary Atresia Therapeutics Market Segmentation

• 9.1. Global Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Surgical Procedures, Medication, Liver Transplantation, Other Treatment Types
• 9.2. Global Biliary Atresia Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Neonates, Infants, Pediatric Patients
• 9.3. Global Biliary Atresia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Other Route Of Administrations
• 9.4. Global Biliary Atresia Therapeutics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users
• 9.5. Global Biliary Atresia Therapeutics Market, Sub-Segmentation Of Surgical Procedures, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Kasai Portoenterostomy, Minimally Invasive Biliary Surgery, Robotic Assisted Biliary Surgery, Revision Surgical Procedures
• 9.6. Global Biliary Atresia Therapeutics Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Corticosteroid Therapy, Antibiotic Therapy, Immunosuppressive Therapy, Bile Acid Therapy, Nutritional Supplement Therapy
• 9.7. Global Biliary Atresia Therapeutics Market, Sub-Segmentation Of Liver Transplantation, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Living Donor Liver Transplantation, Deceased Donor Liver Transplantation, Split Liver Transplantation, Pediatric Liver Retransplantation
• 9.8. Global Biliary Atresia Therapeutics Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Supportive Nutritional Care, Post Operative Care Management, Pediatric Hepatology Monitoring, Palliative Care Services

10. Biliary Atresia Therapeutics Market Regional And Country Analysis

• 10.1. Global Biliary Atresia Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Biliary Atresia Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Biliary Atresia Therapeutics Market

• 11.1. Asia-Pacific Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Biliary Atresia Therapeutics Market

• 12.1. China Biliary Atresia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Biliary Atresia Therapeutics Market

• 13.1. India Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Biliary Atresia Therapeutics Market

• 14.1. Japan Biliary Atresia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Biliary Atresia Therapeutics Market

• 15.1. Australia Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Biliary Atresia Therapeutics Market

• 16.1. Indonesia Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Biliary Atresia Therapeutics Market

• 17.1. South Korea Biliary Atresia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Biliary Atresia Therapeutics Market

• 18.1. Taiwan Biliary Atresia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Biliary Atresia Therapeutics Market

• 19.1. South East Asia Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Biliary Atresia Therapeutics Market

• 20.1. Western Europe Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Biliary Atresia Therapeutics Market

• 21.1. UK Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Biliary Atresia Therapeutics Market

• 22.1. Germany Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Biliary Atresia Therapeutics Market

• 23.1. France Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Biliary Atresia Therapeutics Market

• 24.1. Italy Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Biliary Atresia Therapeutics Market

• 25.1. Spain Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Biliary Atresia Therapeutics Market

• 26.1. Eastern Europe Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Biliary Atresia Therapeutics Market

• 27.1. Russia Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Biliary Atresia Therapeutics Market

• 28.1. North America Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Biliary Atresia Therapeutics Market

• 29.1. USA Biliary Atresia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Biliary Atresia Therapeutics Market

• 30.1. Canada Biliary Atresia Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Biliary Atresia Therapeutics Market

• 31.1. South America Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Biliary Atresia Therapeutics Market

• 32.1. Brazil Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Biliary Atresia Therapeutics Market

• 33.1. Middle East Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Biliary Atresia Therapeutics Market

• 34.1. Africa Biliary Atresia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Biliary Atresia Therapeutics Market, Segmentation By Treatment Type, Segmentation By Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Biliary Atresia Therapeutics Market Regulatory and Investment Landscape

36. Biliary Atresia Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Biliary Atresia Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Biliary Atresia Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Biliary Atresia Therapeutics Market Company Profiles
  • 36.3.1. Ipsen S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Mirum Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. CANbridge Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

38. Global Biliary Atresia Therapeutics Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Biliary Atresia Therapeutics Market

41. Biliary Atresia Therapeutics Market High Potential Countries, Segments and Strategies

• 41.1 Biliary Atresia Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Biliary Atresia Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Biliary Atresia Therapeutics Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer